There are reports of T1DM with CTLA‐4 inhibitor use, but the incidence appears to be far lower than in PD‐1 inhibitor monotherapy or PD‐1/CTLA‐4 inhibitor combination therapy [8]. Here, CTLA4 is linked to type 1 diabetes mellitus.